Outcomes are reported from a study undertaken in late 2013/early 2014 to determine the feasibility of using the AliveCor® iPhone heart monitor to screen for undiagnosed atrial fibrillation (AF) in a high-risk primary care population, using a community pharmacist in Auckland as the first point of contact for screening. The study recruited 121 Māori and Pacific people aged ≥55 years who visited the All Seasons Pharmacy in Te Atatu, Auckland. Twenty participants were found to have AF upon screening (7 Māori and 13 Pacific people). Two people screened had a new diagnosis of AF and 2 known AF cases appeared not to be receiving warfarin. The heart monitor was considered easy to use by both pharmacists and participants, and participating GPs gave overwhelmingly positive feedback on the study. A larger NZ study is planned to verify these results.